Aeglea BioTherapeutics, a company specializing in clinical-stage biotechnology, is making waves in the realm of rare metabolic disease treatment. They have developed groundbreaking human enzyme therapeutics, such as pegtarviliase and pegzilarginase, which are in Phase I/II and Phase III PEACE trials respectively. While pegtarviliase is designed to help patients with homocystinuria, pegzilarginase aims to provide a safe and effective treatment for people suffering from Arginase 1 deficiency. The company also boasts a promising preclinical pipeline, which includes AGLE-325 for the treatment of cystinuria and other research programs. Founded in 2013 and headquartered in Austin, Texas, Aeglea BioTherapeutics was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015.
Aeglea BioTherapeutics, Inc.'s ticker is AGLE
The company's shares trade on the NASDAQ stock exchange
They are based in Austin, Texas
There are 51-200 employees working at Aeglea BioTherapeutics, Inc.
It is https://aeglea.com/
Aeglea BioTherapeutics, Inc. is in the Healthcare sector
Aeglea BioTherapeutics, Inc. is in the Biotechnology industry
The following five companies are Aeglea BioTherapeutics, Inc.'s industry peers: